Abstract:Context Transarterial chemoembolization ( TACE) combined with radiofrequency ablation ( RFA) therapy has been used for patients with large hepatocellular carcinoma tumors, but the survival benefits of combined treatment are not known.Objective To compare rates of survival of patients with large hepatocellular carcinoma tumors who received treatment with TACE combined with RFA therapy ( TACE- RFA), TACE alone, and RFA alone.Design, Setting, and Patients Randomized controlled trial conducted from January 2001 to May 2004 among 291 consecutive patients with hepatocellular carcinoma larger than 3 cm at a single center in China.Intervention Patients were randomly assigned to treatment with combined TACE- RFA ( n= 96), TACE alone ( n= 95), or RFA alone ( n= 100).Main Outcome Measures The primary end point was survival and the secondary end point was objective response rate.Results During a median 28.5 months of follow- up, median survival times were 24 months in the TACE group ( 3.4 courses), 22 months in the RFA group ( 3.6 courses), and 37 months in the TACE- RFA group ( 4.4 courses). Patients treated with TACE-RFA had better overall survival than those treated with TACE alone ( hazard ratio [ HR], 1.87; 95% confidence interval [ CI], 1.33- 2.63; P <. 001) or RFA ( HR, 1.88; 95% CI, 1.34- 2.65; P <. 001). In a preplanned substratification analysis, survival was also better in the TACE- RFA group than in the RFA group for patients with uninodular hepatocellular carcinoma ( HR, 2.50; 95% CI, 1.42- 4.42; P=. 001) and in the TACE- RFA group than the TACE group for patients with multinodular hepatocellular carcinoma ( HR, 1.99; 95% CI, 1.31- 3.00; P <. 001). The rate of objective response sustained for at least 6 months was higher in the TACE- RFA group ( 54%) than with either TACE ( 35%; rate difference, 0.19; 95% CI, 0.06- 0.33; P=. 009) or RFA ( 36%; rate difference, 0.18; 95% CI, 0.05- 0.32; P=. 01) treatment alone.Conclusion In this patient group, TACE- RFA was superior to TACE alone or RFA alone in improving survival for patients with hepatocellular carcinoma larger than 3 cm.Trial Registration clinicaltrials. gov Identifier: NCT00479050.

External-beam Radiotherapy after Transarterial Chemoembolization (TACE) Versus TACE Alone for Treatment of Inoperable HCC: A Randomized Phase III Trial

Three-dimensional Conformal Radiotherapy in Combination with Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma.

External Beam Radiation therapy After Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone for Treatment of Inoperable Hepatocellular Carcinoma: A Randomized Phase 3 Trial

Randomized Clinical Trial of Transcatheter Arterial Chemoembolization Plus Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Intermediate Stage (BCLC Stage B) Hepatocellular Carcinoma Beyond Milan Criteria.

Chemoembolization Combined with Radiofrequency Ablation for Patients with Hepatocellular Carcinoma Larger Than 3 Cm: a Randomized Controlled Trial.

The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma

Radiofrequency Ablation with or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: a Prospective Randomized Trial.

Effect of external beam radiation therapy versus transcatheter arterial chemoembolization for non-diffuse hepatocellular carcinoma (≥ 5 cm): a multicenter experience over a ten-year period

Transarterial Chemoembolization Combined with Molecularly Targeted Agents Plus Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: a Retrospective Cohort Study.

Retracted: Chemoembolization Combined With Radiofrequency Ablation For Patients With Hepatocellular Carcinoma Larger Than 3 Cm - A Randomized Controlled Trial (Retracted Article. See Vol. 301, Pg. 1931, 2009)

Efficacy of Radiation Plus Transarterial Chemoembolization and Lenvatinib in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

Clinical study of transarterial chemoembolization combined with 3-dimensional conformal radiotherapy for hepatocellular carcinoma

Comparison Between Chemoembolization Combined with Radiotherapy and Chemoembolization Alone for Large Hepatocellular Carcinoma

Effect of Transarterial Chemoembolization Plus Percutaneous Ethanol Injection or Radiofrequency Ablation for Liver Tumors

3D Conformal Radiotherapy Combined with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Transcatheter Chemoembolization Plus Percutaneous Radiofrequency Ablation Versus Laparoscopic Radiofrequency Ablation: Improved Outcome for Inoperable Hepatocellular Carcinoma

Combined Hepatectomy and Radiofrequency Ablation Versus TACE in Improving Survival of Patients with Unresectable BCLC Stage B HCC.

Long-term Outcomes of Transcatheter Arterial Chemoembolization Combined With Radiofrequency Ablation as an Initial Treatment for Early-Stage Hepatocellular Carcinoma

Transarterial Chemoembolization for the Treatment of Advanced-Stage Hepatocellular Carcinoma

Single-Agent Versus Combination Doxorubicin-Based Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Single-Blind, Randomized, Phase Ii Trial

External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer]